Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_assertion type Assertion NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_head.
- NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_assertion description "[Here in a double-blind, placebo-controlled, randomized study, we show that the long-term administration of the angiotensin II type 1 receptor antagonist candesartan in patients with hypertrophic cardiomyopathy was associated with the significant regression of left ventricular hypertrophy, improvement of left ventricular function, and exercise tolerance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_provenance.
- NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_assertion evidence source_evidence_literature NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_provenance.
- NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_assertion SIO_000772 19074594 NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_provenance.
- NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_assertion wasDerivedFrom befree-20140225 NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_provenance.
- NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_assertion wasGeneratedBy ECO_0000203 NP385792.RAKzaHMWxPA8uTAVhIJ6I2O_9WHJS4Lq3V21gXJhs785M130_provenance.